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Pharmacogenomics, once hailed as a futuristic approach to pharmacotherapy, has
transitioned to clinical implementation. Although logistic and economic limitations
to clinical pharmacogenomics are being superseded by external measures such
as preemptive genotyping, implementation by clinicians has met resistance, partly
due to a lack of education. Pharmacists, with extensive training in pharmacology
and pharmacotherapy and accessibility to patients, are ideally suited to champion
clinical pharmacogenomics. This study aimed to analyze the outcomes of an
innovative pharmacogenomic teaching approach. Second-year student pharmacists
enrolled in a required, 15-week pharmaceutical care lab course in 2015 completed
educational activities including lectures and small group work focusing on practical
pharmacogenomics. Reflecting the current landscape of direct-to-consumer (DTC)
genomic testing, students were offered 23andMe genotyping. Students completed
surveys regarding their attitudes and confidence on pharmacogenomics prior to and
following the educational intervention. Paired pre- and post-intervention responses were
analyzed with McNemar’s test for binary comparisons and the Wilcoxon signed-rank
test for Likert items. Responses between genotyped and non-genotyped students
were analyzed with Fisher’s exact test for binary comparisons and the Mann-Whitney
U-test for Likert items. Responses were analyzed for all student pharmacists who
voluntarily completed the pre-intervention survey (N = 121, 83% response) and for
student pharmacists who completed both pre- and post-intervention surveys (N = 39,
27% response). Of those who completed both pre- and post-intervention surveys,
59% obtained genotyping. Student pharmacists demonstrated a significant increase
in their knowledge of pharmacogenomic resources (17.9 vs. 56.4%, p < 0.0001)
and confidence in applying pharmacogenomic information to manage patients’ drug
therapy (28.2 vs. 48.7%, p = 0.01), particularly if the student had received genotyping.
Student pharmacists understanding of the risks and benefits of using personal genome
testing services significantly increased (55.3 vs. 86.8%, p = 0.001) along with
agreement that personal genomics would likely play an important role in their future
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career (47.4 vs. 76.3%, p = 0.01), particularly among students who participated in
genotyping. The educational intervention, including personal genotyping, was feasible,
and positively enhanced students’ reflections, and attitudes toward pharmacogenomics
in a professional pharmacy program.
Keywords: pharmacogenomics education, direct-to-consumer personal genotyping, clinical pharmacogenomics
implementation, student pharmacists, preemptive genotyping
INTRODUCTION
The political, social, and economic landscape of personalized
medicine, particularly pharmacogenomics, is in the midst of a
transformation. In early 2015, plans for the landmark Precision
Medicine Initiative (PMI) were established with the goal to
advance biomedical precision medicine research and broaden
personalized treatment. This initiative included a $215 million
investment in the National Institutes of Health (NIH), the Food
and Drug Administration (FDA), and the National Coordinator
for Health Information Technology (ONC, Jaffe, 2015; Printz,
2015).
Additional factors such as direct-to-consumer (DTC) personal
genotyping and reduced cost for sequencing have brought
pharmacogenomics to the forefront of regulatory and public
attention. Along these lines, the FDA has increased regulation
of personalized genome testing companies. Marketing approval
for several DTC personal genome tests, classified as medical
devices by the FDA, have been required to substantiate safety
and efficacy claims and mitigate risk (Lancet, 2008; Nature,
2013). These regulatory actions have a direct effect on how
pharmacogenomics is used in the clinic. The public will also drive
clinical pharmacogenomics as consumers of these DTC personal
genome tests (Chua and Kennedy, 2012).
Pharmacogenomics, once hailed as a futuristic approach
to medical treatment, has begun to transition from discovery
of gene variant-drug pairs to implementation in the clinic
(Collins et al., 2003; Collins, 2010). FDA-recommended
pharmacogenomic information has been included in the label for
nearly 140 drugs (http://www.fda.gov/Drugs/ScienceResearch/
ResearchAreas/Pharmacogenetics/ucm083378.htm, US Food
and Drug Administration). Additionally, guidelines exist
via groups, namely the Pharmacogenomics Knowledgebase
(PharmGKB at https://www.pharmgkb.org/index.jsp) and
the Clinical Pharmacogenomics Implementation Consortium
(CPIC at https://cpicpgx.org/), tasked with determining the
clinical impact of gene-variant-drug pairs in the medical
community (PGRN, Relling and Klein, 2011; Shuldiner
et al., 2013). The amount of individuals with potentially
actionable pharmacogenomic variants is massive; in 2013,
∼750 million prescriptions in the United States were issued for
pharmacogenetically high-risk drugs, and 99% of the population
is estimated to have a high-risk variant for a gene associated
with these drugs (Dunnenberger et al., 2015). Additionally,
numerous somatic mutations have been discovered with
a direct role in targeted oncologic/hematologic treatments
(Relling and Evans, 2015). However, implementation of
pharmacogenomics testing in the clinic has been hindered by
logistical and economic limitations. Several research institutes
and associated medical centers have begun implementing
preemptive pharmacogenomics to alleviate limitations of reactive
genotyping. Still with these external influences, clinicians have
shown resistance to implementing pharmacogenomics, partly
due to a lack of education in genetics and its use in pharmacy
(Nickola et al., 2012).
Pharmacists, with extensive training in pharmacology, and
pharmacotherapy and accessibility to patients are ideally suited to
champion clinical pharmacogenomics (McCullough et al., 2011;
Nickola et al., 2012; Owusu-Obeng et al., 2014; Rao et al., 2015).
Several pharmacy programs have acknowledged the importance
of pharmacogenomics in the core curriculum. Furthermore,
student pharmacists may benefit by educational interventions
early in the curriculum to build a foundation for advanced
discussion (Moen and Lamba, 2012; Nickola andMunson, 2014a;
Lee et al., 2015). An increase in pharmacogenomics instruction
is due partly to shifts in established curriculum guidelines (i.e.,
the American Association of Colleges of Pharmacy, Johnson
et al., 2002) and recognition by pharmacy organizations (e.g.,
the American College of Clinical Pharmacy and American
Society of Health System Pharmacists, ASHP 2015) as a
necessary clinical skill in the workplace requiring minimal
competencies in proficiency (Rao et al., 2015). In this study,
student pharmacists were surveyed regarding their attitudes and
self-perceived competencies on pharmacogenomics prior to an
educational intervention focusing on the practical applications
of pharmacogenomics in the clinical setting. Also to reflect the
current landscape of DTC genomic testing, student pharmacists
were offered the opportunity to obtain DTC genotyping using
23andMe kits. Student pharmacists were then surveyed following
the educational intervention and the opportunity to receive
genotyping results.
MATERIALS AND METHODS
Subjects
Subjects were student pharmacists in their 2nd year of
professional pharmacy education in the Eshelman School of
Pharmacy at the University of North Carolina (UNC) at Chapel
Hill. The cohort included students on both the Chapel Hill and
Asheville campuses who were enrolled in a required 15-week
course titled Pharmacy 404L: Pharmaceutical Care Lab during
the Spring 2015 semester. One hundred forty-five students were
enrolled in the course, and participation in this study was
voluntary. This study was determined to be exempt from review
by the UNC Institutional Review Board and was conducted in
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accordance to Good Clinical Practice, International Conference
of Harmonization guidelines, and all applicable state and federal
laws.
Pharmacogenomics Educational
Interventions
Pharmaceutical Care Lab consisted of weekly, 1-h large
group class sessions for all 145 students and weekly, 4-h
small group sessions of 8–10 students led by a pharmacy
post-graduate resident. On week 8 of the course, during a
1-h large group lecture, student pharmacists completed a
pre-intervention survey, participated in an introductory lecture
on pharmacogenomics, and received information regarding
voluntary and anonymous personal genomic testing via 23andMe
(Mountain View, CA). The large group lecture included the
following student learning objectives: define pharmacogenomics,
discuss the importance of pharmacogenomics in drug therapy,
examine how pharmacogenomics is used to manage drug
therapy, and provide examples of pharmacogenomic-guided
algorithms. On week 11 of the course, pharmacogenomic cases,
and relevant clinical resources were discussed in small group
sessions. Pharmacy residents facilitated case discussions and were
provided with an instructor’s guide. A final wrap-up large group
lecture was provided on week 15 with the following student
learning objectives: discuss 23andMe results, demonstrate how
to obtain pertinent pharmacogenomic information and utilize
online resources, and review a clinical case focusing on the
use of pharmacogenomics to manage drug therapy. Overall,
eight different drug-gene pairs were described using clinical
cases. Student pharmacists were asked to complete the post-
intervention survey immediately following this final lecture. A
detailed outline of the educational intervention is presented in
Supplementary Table 1.
Personal Genome Testing
The voluntary 23andMe personal genome test was offered to
student pharmacists at a reduced price of $30.00 through
funding from the UNC Center for Pharmacogenomics and
Individualized Therapy (CPIT). Student pharmacists signed
up for genotyping online, and kits were sent directly to
their residences from 23andMe. Student pharmacists collected
samples and sent them back to 23andMe, after which they
received their results ∼4–6 weeks later via the 23andMe
website. At the time of the completion of this study, 23andMe
provided information limited to ancestry and raw data from
the Illumina R© HumanOmniExpress-24 format chip consisting
of 730,525 markers (San Diego, CA). Student pharmacists
received results for 23andMe prior to the conclusion of the
course. They were instructed on how to use the 23andMe
website and download raw data but were also provided with
demo profile information if they opted out of testing. Student
pharmacists were referred to third party websites for detailed
health information along with precautions and limitations of
using various online resources. Student pharmacists extracted
personal pharmacogenomic data from the raw 23andMe
genotype file using an Excel spreadsheet developed by our lab
and interpreted data using the PharmGKB and CPIC guidelines
(https://www.pharmgkb.org/). The spreadsheet was designed
using gene haplotype translation tables from PharmGKB to
assign haplotypes to CYP2C19, CYP2C9, CYP3A5, CYP2D6,
DPYD, TPMT, G6PD, IFNL3, SLCO1B1, and VKORC1. For
each gene, when no changes from the reference haplotype
were identified, the formula returned the reference haplotype; if
haplotypes could not be determined due to missing or conflicting
information, no haplotypes were reported. The limitations of
the spreadsheet and the 23andMe genotyping were explained
in the informational sheet along with the identified haplotypes.
Hyperlinks to CPIC guideline webpages for the various drugs
affected by the genes were included in the spreadsheet. Extensive
office hours were offered to student pharmacists pre- and post-
genotyping. Although not requested, referrals for follow-up
health appointments to discuss specific concerns were available.
Survey
An electronic survey (Supplementary File 1) was administered
at the start of our pharmacogenomic-focused educational
intervention during week 8 of the course, and the same survey
was repeated with additional prompts at the conclusion of the
course on week 15. The survey instrument was adapted from
Ormond et al., Salari et al., and Lee et al. with slight modifications
to target our student pharmacist audience (Ormond et al.,
2011; Salari et al., 2013; Lee et al., 2015). The survey requested
demographic information and assessed prior exposure to basic
and clinical genetics. Also, student pharmacists’ personal and
professional attitudes and self-perceived confidence with regards
to clinical pharmacogenomics and personal genome testing
were assessed. The survey included yes/no and yes/no/maybe
questions. Additionally, the survey asked for a level of agreement
with various statements using a five-point Likert scale (i.e.,
strongly agree, agree, neither agree nor disagree, disagree, and
strongly disagree).
Statistical Analysis
Responses were analyzed for all student pharmacists who
completed the pre-intervention survey. Items assessed on a
five-point Likert scale were collapsed and presented as the
number and percentage of student pharmacists agreeing or
strongly agreeing with the corresponding statement. Exploratory
analyses were included for student pharmacists who completed
both the pre- and post-intervention surveys (referred to as the
linked subset group). Student pharmacist responses were linked
using an alphanumeric code to preserve anonymity. Paired pre-
and post-intervention responses were analyzed with McNemar’s
test for binary comparisons and the Wilcoxon signed-rank
test for Likert items. Responses between genotyped and non-
genotyped students were analyzed with Fisher’s exact test for
binary comparisons and the Mann-Whitney U-test for Likert
items. Results were considered statistically significant if p < 0.05.
RESULTS
Study Population Demographics
Demographics for the study population are presented in Table 1.
Responses were analyzed for all student pharmacists who
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TABLE 1 | Study population demographics.
Characteristics Pre-intervention Linked subset Genotyped Non-genotyped
(N = 121) (N = 39) (N = 23) (N = 16)
Age (Median and Range) 24 (21–47) 25 (21–41) 25 (21–41) 24 (22–33)
ETHNICITY
Asian 23 (19.3) 4 (10.3) 2 (8.7) 2 (12.5)
Black or African American 8 (6.6) 3 (7.7) 2 (8.7) 1 (6.3)
Hispanic or Latino 4 (3.3) 3 (7.7) 3 (13) 0 (0)
Native Hawaiian or Pacific Islander 1 (0.8) 0 (0) 0 (0) 0 (0)
White or Caucasian (Not Hispanic or Latino) 89 (73.6) 30 (76.9) 16 (69.6) 14 (87.5)
HIGHEST LEVEL OF EDUCATION OBTAINED PRIOR TO PHARMACY SCHOOL
Undergraduate coursework 26 (21.5) 6 (15.4) 3 (13) 3 (18.8)
Associate degree 2 (1.7) 1 (2.6) 0 (0) 1 (6.3)
Bachelor degree 83 (68.6) 30 (76.9) 19 (82.6) 11 (68.8)
Graduate degree 8 (6.6) 1 (2.6) 1 (4.3) 0 (0)
Professional degree 2 (1.7) 1 (2.6) 0 (0) 1 (6.3)
Genetics course in past 73 (60.3) 28 (71.8) 14 (60.9) 14 (87.5)
The number (and percentage) of subjects with each corresponding characteristic is reported. Fisher’s exact test was used to compare genotyped and non-genotyped subjects, and
there were no statistically significant differences.
completed the pre-intervention survey (N = 121, 83% response
rate). The post-intervention survey response rate was 35%
(N = 51). We focused our analyses on a linked subset of student
pharmacists who completed both the pre- and post-intervention
surveys (N = 39, 27%). This comparison subset was further
delineated into the genotyped group (N = 23 or 22 for the last
prompts regarding personal genome testing) and non-genotyped
group (N = 16, Supplementary Figure 1).
The class consisted of 2nd-year student pharmacists with a
median age of 24 years (ranging from 21 to 47 years). Student
pharmacists self-described their ethnicity as 73.6% “White or
Caucasian (not Hispanic or Latino),” 19.3% “Asian,” 6.6% “Black
or African American,” 3.3% “Hispanic or Latino,” and 1%
“Native Hawaiian or Pacific Islander.” The majority of student
pharmacists reported having obtained a bachelor degree prior
to pharmacy school (68.6%) and having taken genetics (60.3%).
One student pharmacist completed personal genotyping using
23andMe prior to the implementation of this study and was
therefore removed from subsequent analyses comparing pre- and
post-intervention groups. There were no statistically significant
differences in demographics between the genotyped and non-
genotyped groups or between those who completed the pre-
intervention survey and students in the linked subset group
who completed both the pre- and post-intervention surveys
(Table 1).
Personal Experience with Clinical Genetics
Prior to the initiation of this study, few 2nd-year student
pharmacists had personal experiences regarding clinical
genetic testing (3.3%), and none had pharmacogenomic testing
performed in a medical setting (Supplementary Table 2).
Compared to personal experience, more student pharmacists
knew someone who had genetic testing (17.4%) or
pharmacogenomic testing (8.3%) in a medical setting.
In the pre-intervention survey, a majority (N = 69, 57%) of
student pharmacists were interested in providing saliva samples
to 23andMe for personal genome testing. However, only 69.6%
(N = 23) of genotyped and 43.8% (N = 7) of non-
genotyped student pharmacists originally affirmed interest in this
personal genotyping opportunity prior to the intervention. There
was not a significant relationship between student pharmacists’
personal experiences with medications and participation in
personal genotyping in our study population; a majority of
student pharmacists were taking medications (67.8%) and had
tried medications that were ineffective (53.7%) or had side
effects (76%).
Personal Reflections and Attitudes toward
Pharmacogenomics
The pre-intervention survey indicated that a majority of
student pharmacists were comfortable with the use of personal
pharmacogenomic information to guide clinicians in selecting
the appropriate medication (73.6%) and dose of medication
(72.7%) for themselves (Table 2). Most student pharmacists
wanted the drug or dosage of their medicine to be selected
or changed based on the results of pharmacogenomic testing
on the pre-intervention survey (89.3%). Student pharmacists
largely agreed that the information from a pharmacogenomic test
could improve the way their medication treatment is currently
managed (86.8%) or will be managed in the future (94.2%). In
the genotyped group, there was a statistically significant decrease
in agreement between the pre- and post-survey that information
from a pharmacogenomic test may improve the way medication
treatment is currently being managed for the student (91.3
vs. 73.9%, p = 0.04, Wilcoxon signed-rank test). There were
no additional statistically significant changes in pre- to post-
intervention survey responses to the five questions focused on
personal reflections and attitudes toward pharmacogenomics.
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Professional Reflections and Attitudes
toward Pharmacogenomics
Overall, student pharmacists agreed that pharmacogenomics
was useful in managing drug therapy in the pre-intervention
survey (85.1%, Table 2), but a smaller proportion of student
pharmacists were confident in their ability to understand the
results of pharmacogenomic testing in the pre-intervention
survey (59.5%). Even fewer student pharmacists were familiar
with pharmacogenomic resources (e.g., guidelines such as those
by the CPIC or PharmGKB) for use in the clinical setting on the
pre-intervention survey (30.6%). However, after the intervention,
student pharmacists in the linked subset group significantly
increased their knowledge of pharmacogenomic resources (17.9
vs. 56.4%, p < 0.0001, Wilcoxon signed-rank test). A significant
difference was upheld in agreement with this statement in
both the genotyped (21.7 vs. 60.9%, p = 0.0007, Wilcoxon
signed-rank test) and non-genotyped groups (12.5 vs. 50%,
p = 0.0002, Wilcoxon signed-rank test). Student pharmacists
would largely recommend pharmacogenomic testing to manage
therapy prospectively on the pre-intervention survey (65.3%), yet
no significant difference was found pre- to post-intervention. A
significantly larger agreement with this statement occurred in
the genotyped group when compared with the non-genotyped
group on the post-intervention survey (82.6 vs. 50%, p = 0.04,
Mann Whitney-U test). A minority of student pharmacists
were confident in applying pharmacogenomic information to
manage patients’ drug therapy on the pre-intervention survey
(39.7%). However, a significant increase in agreement with this
statement was present within the pre- to post-intervention linked
subset survey group (28.2 vs. 48.7%, p = 0.01, Wilcoxon
signed-rank test) and particularly with the student pharmacists
who were genotyped (21.75 vs. 56.5%, p = 0.002, Wilcoxon
signed-rank test). Most students agreed that pharmacogenomic
information should be stored in the patient’s medical record
on the pre-intervention survey (85.1%). However, a decrease in
agreement with this statement occurred from the pre- to post-
intervention linked subset surveys (92.3 vs. 79.5%, p = 0.0096,
Wilcoxon signed-rank test). Student pharmacists largely agreed
that pharmacogenomics would likely play an important role in
their future careers (77.7%).
Overall, student pharmacists agreed that patients and
healthcare providers (e.g., physicians, pharmacists, and nurses)
should have access to the results of pharmacogenomic tests.
From the pre- to post-intervention linked subset surveys, similar
percentages of student pharmacists agreed that patients (98 vs.
93%), healthcare providers (100 vs. 95%), and health insurance
companies (18 vs. 23%) should have access. On the pre-
intervention survey, few student pharmacists agreed that life
insurance companies (10.7%) and family members (0.8%) should
have access.
On the post-intervention survey, genotyped and non-
genotyped student pharmacists were asked if they could explain
the rationale for pharmacogenomic testing (82.6 vs. 62.5%),
identify therapeutic areas in which pharmacogenomic testing
is required (65.2 vs. 56.3%) or recommended (78.3 vs. 56.3%),
discuss the risks and benefits of pharmacogenomic testing
(73.9 vs. 56.3%), and interpret the results of pharmacogenomic
testing from patients (43.5 vs. 37.5%, Table 3). However, there
were no statistically significant differences for these findings
between the genotyped and non-genotyped groups. To this
end, on the post-intervention survey, student pharmacists
were questioned about including future pharmacogenomics
TABLE 3 | Self-perceived confidence in pharmacogenomics.
Question Genotyped group Non-genotyped group Genotyped group (N = 23) vs.
(N = 23) (N = 16) non-genotyped group (N = 16)
I can explain the rationale for pharmacogenomic testing
in various therapeutic areas to patients.
19 (82.6) 10 (62.5) 0.0932
I can identify therapeutic areas in which
pharmacogenomic testing is required.
15 (65.2) 9 (56.3) 0.3092
I can identify therapeutic areas in which
pharmacogenomic testing is recommended.
18 (78.3) 9 (56.3) 0.5058
I can discuss the risks and benefits of pharmacogenomic
testing with patients.
17 (73.9) 9 (56.3) 1
I can interpret the results of pharmacogenomic testing
from patients.
10 (43.5) 6 (37.5) 0.2455
The pharmacy profession should be more active in
educating patients and other healthcare providers about
pharmacogenomics.
18 (78.3) 7 (43.8) 0.2797
Would recommend a personal genotyping test for a
patient.
6 (26.1) 6 (37.5) 0.498
Responses between genotyped and non-genotyped students were analyzed with the Mann-Whitney U-test, and there were no statistically significant differences.
Frontiers in Pharmacology | www.frontiersin.org 7 August 2016 | Volume 7 | Article 241
Frick et al. Pharmacogenomics Training for Future Pharmacists
material/activities in Pharmaceutical Care Lab and in the
pharmacy curriculum (Supplementary Table 3). Only 23.1% of
students were satisfied with the amount of time spent on
pharmacogenomics in Pharmaceutical Care Lab. Additionally,
few student pharmacists were satisfied with the amount of
time (35.9%) or agreed that more time should be spent
on pharmacogenomics in the curriculum (30.8%). Student
pharmacists largely agreed that an elective pharmacogenomics
course should be available in the curriculum (53.8%) and that
pharmacogenomics should be covered as needed in therapeutic
coursework (56.4%).
Reflections and Attitudes toward Personal
Genotyping
A slight majority of students agreed with understanding the
risks and benefits of using personal genome testing services
in the pre-intervention group (52.1%, Table 2). A significant
increase in agreement with this statement occurred between
the pre- and post-intervention linked subset surveys (55.3 vs.
86.8%, p = 0.001, Wilcoxon signed-rank test), particularly
in the non-genotyped group (37.5 vs. 81.3%, p = 0.016,
Wilcoxon signed-rank test). Again, a slight majority of student
pharmacists indicated that they knew enough about genetics
to understand personal genome results in the pre-intervention
group (51.2%). Student pharmacists in the pre-intervention
group largely agreed that personal genomics would likely play
an important role in their future careers (61.2%). A significant
increase in student pharmacist agreement occurred with this
prompt between the pre- and post-intervention surveys in the
linked subset group (47.4 vs. 76.3%, p = 0.013, Wilcoxon
signed-rank test). This significant increase was upheld between
the pre- and post-intervention surveys of the linked subset for
the genotyped group (54.5 vs. 86.4%, p = 0.047, Wilcoxon
signed-rank test) and between the genotyped and non-genotyped
post-intervention groups (86.4 vs. 62.5%, p = 0.041, Mann
Whitney-U test). In the pre-intervention survey, few student
pharmacists agreed that physicians and pharmacists have enough
knowledge to help individuals interpret the results of their
personal genome tests (respectively, 23.1 and 25.6%). Few student
pharmacists agreed that most people could accurately interpret
their personal genome test results on the pre-intervention
survey (4.1%), which did not significantly change in the
post-intervention survey. Few student pharmacists agreed that
personal genome testing companies provide an accurate analysis
and interpretation of genotype data on the pre-intervention
survey (19.8%). The majority of student pharmacists in the
pre-intervention subset agreed that personal genome testing
companies should be regulated by the federal government (i.e.,
the FDA, 61.2%).
Twenty-three student pharmacists (59%) in the post-
intervention survey group indicated that they had provided
saliva samples to 23andMe for personal genome testing. The
most common reasons for undergoing personal genotyping
included satisfying general curiosity about their genetic
makeup (96%), learning about their ancestry (83%), gaining
access to their raw genetic data for further analysis (74%),
and price (52%). Reasons for not undergoing personal
genotyping in the post-intervention survey group included
not being curious about their genetic makeup (35%), not
wanting to learn about their ancestry (18%), not wanting
access to raw genetic data that could be used to inform
them of future risks (35%), and price (53%). Of the 16
non-genotyped student pharmacists in the post-intervention
survey group, 35% of students responded “yes” and 41%
responded “maybe” when asked if they wished that they had
undergone personal genotyping as a part of Pharmaceutical
Care Lab.
An additional set of prompts was presented to those
student pharmacists who elected to undergo personal genome
testing through this course (Supplementary Table 4). Student
pharmacists in the post-intervention genotyped group agreed
that undergoing personal genome testing enhanced their learning
experience (65%) and that they had a better understanding of
pharmacogenomics on the basis of undergoing personal genome
testing (60.9%). Most student pharmacists agreed that the cost
($30.00) for personal genome testing was reasonable, but few
(13%) would be willing to pay the full price ($99.00 plus shipping
and handling at the time of this study) for personal genome
testing. Less than half of the genotyped group agreed that
undergoing personal genotyping was an important part of their
learning in Pharmaceutical Care Lab (47.8%).
A majority of genotyped students agreed that the
pharmaceutical care lab course helped them understand
what a patient’s experience might be like if they chose to undergo
personal genome testing (78.3%). Overall, student pharmacists
were pleased with their decision to undergo personal genome
testing (87%). Few experienced anxiety when deciding to
undergo personal genome testing (13%) or when waiting for
their results (4.3%), and none experienced anxiety after receiving
personal genome testing results. Most student pharmacists
agreed that the opportunity to ask a healthcare professional for
help in interpreting the results is an important component to a
personal genome testing offer (82.6%).
DISCUSSION
The landscape of clinical pharmacogenomics is rapidly
changing. Pharmacists have indicated a desire to increase
pharmacogenomics-related responsibilities, including
advising clinicians and patients on pharmacogenomics-
guided therapeutic selection and adjustment (Owusu-Obeng
et al., 2014). Furthermore, proof-of-concept studies have
demonstrated that pharmacists, arguably the most accessible
health care provider, can feasibly provide pharmacogenomics
counseling as an extension of medication therapy management
services (Ferreri et al., 2014; O’Connor et al., 2015). Given
that pharmacogenomic profiles will not likely change during
the lifetime of an individual, several medical centers are
implementing preemptive pharmacogenomics to counteract
disadvantages related to reactive pharmacogenomic testing
(Dunnenberger et al., 2015). Personal genotyping companies
have already begun to capitalize on cardiology, psychiatry, and
Frontiers in Pharmacology | www.frontiersin.org 8 August 2016 | Volume 7 | Article 241
Frick et al. Pharmacogenomics Training for Future Pharmacists
pain pharmacogenomics testing in the independent and retail
chain community pharmacy setting (Business Wire, 2015).
Several educational initiatives have been proposed for
fulfilling pharmacist competencies in pharmacogenomics,
ranging from more traditional approaches, such as increased
didactic coursework and case studies, to more innovative
learning methods, such as massive open online courses
(PharmGENEd, Ma et al., 2013) and personal genotyping,
through opportunities such as PGx Test 2 LearnTM (Adams et al.,
2016). Rao et al. identified four strategies for implementation
of an effective pharmacogenomics educational program for
student pharmacists: inclusion of a preadmission genetics
course, establishment of a pharmacogenomics core course in the
curriculum, introduction of an experimental laboratory research
curriculum, and delivery of didactic material and laboratory
rotations by pharmacogenomic experts (Rao et al., 2015). In
addition to personal genome testing, the research presented in
this study focused on the latter strategy identified by Rao and
colleagues. In the open-ended portion of the survey, multiple
student pharmacists stated that pharmacogenomics would
become a more established topic in the future and that student
pharmacists are not taught enough about its future implications.
In terms of improving learning about pharmacogenomics,
multiple students agreed that more time should be devoted to
pharmacogenomics. One student pharmacist aptly commented,
“We need to learn more about [pharmacogenomics] as
pharmacists because more and more companies [. . . ] are
offer[ing] pharmacogenomics testing and this is a problem if
clinicians are behind in knowing how to handle these situations.”
These responses indicate continued need by schools of pharmacy
to assess effective means to educate student pharmacists about
clinical pharmacogenomics. A follow-up study on this topic is
currently underway by our team to delineate improvement in
student learning.
Increased availability and visibility of genomics to the
general public via DTC advertising may become the ultimate
driver of mainstream pharmacogenomics (Chua and Kennedy,
2012). In this study, 23andMe was used as the genotyping
platform for students to obtain personal pharmacogenomic
information. Use of this service reflects the current DTC
environment. Other educational programs have had students
undergo personal testing of innocuous genes unrelated to
pharmacy therapeutics (Nickola and Munson, 2014b). However,
obtaining pharmacogenomics information from 23andMe
provides a more practical snapshot of information student
pharmacists may encounter as future clinicians. The service
also easily enabled blinding as no personal information derived
from the genotyping was collected from the class. Additional
educational programs incorporating pharmacogenomic testing
into the curriculum have collected genomic information
from students in aggregate (O’Brien et al., 2009; Nickola
et al., 2012); however, the approach used in this study further
mitigated disclosure risk. No students experienced anxiety
after receiving their 23andMe reports, which could be partly
attributable to a reduction in incidental findings, as 23andMe
did not report health risks at the time of this study. We
did include mock patient profiles for those students who
opted out of 23andMe testing so they would be able to, at
least partially, participate in this portion of the educational
intervention. Of note, UNC CPIT subsidized the cost of
23andMe testing. However, subsidizing the cost could possibly
encourage students to be genotyped due to the inability or
unwillingness of students to pay for these services on their
own. Furthermore, 23andMe personal genome testing was not
developed specifically for pharmacogenomics. An inexpensive
preemptive pharmacogenomics platform is being developed by
the UNC CPIT to counteract this limitation for implementation
in future educational interventions.
In this study, the survey instrument was adapted from the
tools developed by Salari et al. and Ormond et al., both of which
were administered to medical and graduate students (Ormond
et al., 2011; Salari et al., 2013). Some discrepancies exist between
results from our survey instrument and those of Salari et al
and Ormond et al., likely due to differences in populations
and educational interventions. In the study by Salari et al,
students who underwent genotyping were more aware of the
risks and benefits of using personal genome testing services.
However, in this study, students in the non-genotyped group
reported an increased self-awareness of these risks and benefits
on the post-intervention survey. Contrary to results by Ormond
et al. and Salari et al. respectively, student pharmacists did not
significantly alter their agreement of health care professionals
(i.e., physicians and pharmacists) or the public being able
to accurately interpret the results of personal genome test
results.
Additional prompts were added due to the student
pharmacist population surveyed in this study. Genotyping
positively influenced confidence in applying pharmacogenomics
information to manage patients’ drug therapy and agreement
that personal genomics would likely play an important role
in students’ future careers. Interestingly, perhaps due to
knowledge of current limitations in pharmacogenomics, a
significantly smaller percentage of students in the linked
subset from pre- to post-intervention surveys agreed that
pharmacogenomics information should be stored in the medical
record.
The survey included an exploratory post-intervention
questionnaire set developed from Lee et al., who established
a train-the-trainer approach for broad-scale dissemination
of pharmacogenomics information to students (Lee et al.,
2015). No significant differences existed between the genotyped
and non-genotyped groups in terms of agreement with
prompts related to the therapeutic use of pharmacogenomics.
Although genotyping did not influence student response,
these questions will be included on the pre-intervention
survey in the future to establish if the outcomes of this
educational intervention compare to the train-the-trainer
approach.
Although this study was conducted at a single institution
with students in a specific professional curriculum, it contributes
to our understanding of how educational interventions can
impact student understanding of personalized genotyping in
the health professions. One limitation of this survey was
a low post-intervention survey response rate, which could
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have resulted in selection bias. Despite this low response
rate, we were able to glean important information about this
intervention. To protect anonymity, surveys were not linked to
grades, making it difficult to determine our impact on student
confidence beyond the student self-reported data collected.
Also, the timing of the post-intervention survey was not
ideal, as the survey was released at the end of the semester.
However, it is a valuable endeavor to continue optimizing this
intervention for 2016, and it is anticipated that this educational
intervention and the offer for personal pharmacogenomic
testing will become a staple within the curriculum. Overall,
the educational intervention, including personal genotyping,
within this study was feasible and positively enhanced reflections
and attitudes toward pharmacogenomics in a professional
capacity.
AUTHOR CONTRIBUTIONS
AF, CSB, KS, CLB, and TW designed and implemented the
educational intervention. AF, CSB, JM, and NW created and
modified the survey instrument. AF and JM analyzed the data,
and OS created the pharmacogenomic tool for students to
analyze their data. All authors contributed to the writing and
editing of this manuscript.
FUNDING
The University of North Carolina Center for Pharmacogenomics
and Individualized Therapy subsidized the cost of 23andMe kits
for student pharmacists.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: http://journal.frontiersin.org/article/10.3389/fphar.
2016.00241
Supplementary Figure 1 | Study participants. The entire 2nd year class of
student pharmacists consisted of 145 individuals. Student pharmacists are
color-coded based on participation: dark blue represents those who only
completed the pre-intervention survey (N = 81), red represents those who
completed both pre- and post-intervention surveys as part of a linked subset
group and were genotyped (N = 23), orange represents those in the linked subset
group who were not genotyped (N = 16), purple represents one student
pharmacist in the linked subset group who was excluded due to prior genotyping
with 23andMe, teal represents those who only completed the post-intervention
survey (N = 12), and gray represents students who did not complete either the
pre- or post-intervention survey (N = 12).
Supplementary Table 1 | Detailed outline of the educational intervention
describing objectives and cases. Through the educational intervention,
students were exposed to eight different drug-gene pair scenarios.
Supplementary Table 2 | Personal experience with clinical genetics. The
number (and percentage) of subject responding “yes” to each corresponding
question is reported. Fisher’s exact test was used to compare genotyped and
non-genotyped subjects, and there were no statistically significant differences.
Supplementary Table 3 | Reflections and attitudes toward
pharmacogenomics in Pharmaceutical Care Lab and the curriculum. Items
were assessed on a five-point Likert scale and were collapsed and presented as
the number (and percentage) of student pharmacists agreeing and strongly
agreeing with the corresponding statement on the post-intervention survey.
Supplementary Table 4 | Reflections and attitudes towards the personal
genome testing experience. Items were assessed on a five-point Likert scale
and were collapsed and presented as the number (and percentage) of genotyped
student pharmacists agreeing and strongly agreeing with the corresponding
statement on the post-intervention survey.
Supplementary File 1 | Survey Instrument.
REFERENCES
Adams, S. M., Anderson, K. B., Coons, J. C., Smith, R. B., Meyer, S. M., Parker, L.
S., et al. (2016). Advancing pharmacogenomics education in the core pharmd
curriculum through student personal genomic testing. Am. J. Pharm. Educ. 80,
1–11. doi: 10.5688/ajpe8013
ASHP (2015). ASHP statement on the pharmacist’s role in clinical
pharmacogenomics. Am. J. Health Syst. Pharm. 72, 579–581. doi:
10.2146/sp150003
Business Wire (2015). Rite Aid First U.S. Drugstore Chain to Offer Harmonyx
Genetic Testing to Customers. Business Wire. Available online at: http://www.
businesswire.com/news/home/20151112005856/en/Rite-Aid-U.S.-Drugstore-
Chain-Offer-Harmonyx
Chua, E. W., and Kennedy, M. (2012). Current state and future prospects
of direct-to-consumer pharmacogenetics. Front. Pharmacol. 3:152. doi:
10.3389/fphar.2012.00152
Collins, F. (2010). Has the revolution arrived? Nature 464, 674–675. doi:
10.1038/464674a
Collins, F. S., Green, E. D., Guttmacher, A. E., and Guyer, M. S. (2003).
A vision for the future of genomics research. Nature 422, 835–847. doi:
10.1038/nature01626
Dunnenberger, H. M., Crews, K. R., Hoffman, J. M., Caudle, K. E., Broeckel,
U., Howard, S. C., et al. (2015). Preemptive clinical pharmacogenetics
implementation: current programs in five US medical centers. Annu. Rev.
Pharmacol. Toxicol. 55, 89–106. doi: 10.1146/annurev-pharmtox-010814-
124835
Ferreri, S. P., Greco, A. J., Michaels, N. M., O’Connor, S. K., Chater, R. W.,
Viera, A. J., et al. (2014). Implementation of a pharmacogenomics service
in a community pharmacy. J. Am. Pharm. Assoc. (2003). 54, 172–179. doi:
10.1331/JAPhA.2014.13033
Jaffe, S. (2015). Planning for US precision medicine initiative underway. Lancet
385, 2448–2449. doi: 10.1016/S0140-6736(15)61124-2
Johnson, J. A., Bootman, J. L., Hudson, R. A., Knoell, D., Simmons,
L., Straubinger, R. M., et al. (2002). Pharmacogenomics: a scientific
revolution in pharmaceutical sciences and pharmacy practice. Report of
the 2001–2002 Academic Affairs Committee. Am. J. Pharm. Educ. 66,
12S–15S.
Lancet (2008). Control of direct-to-consumer genetic testing. Lancet 372, 1360.
doi: 10.1016/S0140-6736(08)61566-4
Lee, K. C., Hudmon, K. S., Ma, J. D., and Kuo, G. M. (2015). Evaluation of a shared
pharmacogenomics curriculum for pharmacy students. Pharmacogenomics 16,
315–322. doi: 10.2217/pgs.14.181
Ma, J. D., Lee, K. C., and Kuo, G. M. (2013). A massive open online course
on pharmacogenomics: not just disruptive innovation but a possible solution.
Pharmacogenomics 14, 1125–1127. doi: 10.2217/pgs.13.97
McCullough, K., Formea, C., Berg, K., Burzynski, J., Cunningham, J., Ou, N.,
et al. (2011). Assessment of the pharmacogenomics educational needs of
pharmacists. Am. J. Pharm. Educ. 75, 1–6.
Moen, M., and Lamba, J. (2012). Assessment of healthcare students’ views on
pharmacogenomics at the University of Minnesota. Pharmacogenomics 13,
1537–1545. doi: 10.2217/pgs.12.139
Nature (2013). The FDA and me. Nature 504, 7–8. doi: 10.1038/504007b
Frontiers in Pharmacology | www.frontiersin.org 10 August 2016 | Volume 7 | Article 241
Frick et al. Pharmacogenomics Training for Future Pharmacists
Nickola, T. J., Green, J. S., Harralson, A. F., and O’Brien, T. J. (2012). The
current and future state of pharmacogenomics medical education in the USA.
Pharmacogenomics 13, 1419–1425. doi: 10.2217/pgs.12.113
Nickola, T. J., and Munson, A. M. (2014a). Pharmacogenomics primer course for
first professional year pharmacy students. Pharmacogenomics 15, 39–48. doi:
10.2217/pgs.13.197
Nickola, T. J., and Munson, A. M. (2014b). Pharmacogenomics primer course for
first professional year pharmacy students. Pharmacogenomics 15, 39–48. doi:
10.2217/pgs.13.197
O’Brien, T. J., Goodsaid, F., Plack, M., Harralson, A., Harrouk, W., Hales,
T. G., et al. (2009). Development of an undergraduate pharmacogenomics
curriculum. Pharmacogenomics 10, 1979–1986. doi: 10.2217/pgs.09.145
O’Connor, S. K., Michaels, N., and Ferreri, S. (2015). Expansion of
pharmacogenomics into the community pharmacy: billing considerations.
Pharmacogenomics 16, 175–180. doi: 10.2217/pgs.14.183
Ormond, K. E., Hudgins, L., Ladd, J. M., Magnus, D.M., Greely, H. T., and Cho,M.
K. (2011). Medical and graduate students’ attitudes toward personal genomics.
Genet. Med. 13, 400–408. doi: 10.1097/GIM.0b013e31820562f6
Owusu-Obeng, A., Weitzel, K. W., Hatton, R. C., Staley, B. J., Ashton, J.,
Cooper-Dehoff, R. M., et al. (2014). Emerging roles for pharmacists in clinical
implementation of pharmacogenomics. Pharmacotherapy 34, 1102–1112. doi:
10.1002/phar.1481
Printz, C. (2015). Precision medicine initiative boosts funding for NCI efforts.
Cancer 121, 3369–3370. doi: 10.1002/cncr.28989
Rao, U. S., Mayhew, S. L., and Rao, P. S. (2015). Strategies for implementation
of an effective pharmacogenomics program in pharmacy education.
Pharmacogenomics 16, 905–911. doi: 10.2217/pgs.15.50
Relling, M. V., and Evans, W. E. (2015). Pharmacogenomics in the clinic. Nature
526, 343–350. doi: 10.1038/nature15817
Relling, M. V., and Klein, T. E. (2011). CPIC: Clinical Pharmacogenetics
Implementation Consortium of the pharmacogenomics research
network. Clin. Pharmacol. Ther. 89, 464–467. doi: 10.1038/clpt.20
10.279
Salari, K., Karczewski, K. J., Hudgins, L., and Ormond, K. E. (2013).
Evidence that personal genome testing enhances student learning in a
course on genomics and personalized medicine. PLoS ONE 8:e68853. doi:
10.1371/journal.pone.0068853
Shuldiner, A. R., Relling, M. V., Peterson, J. F., Hicks, K., Freimuth, R.
R., Sadee, W., et al. (2013). The pharmacogenomics research network
translational pharmacogenetics program: overcoming challenges of real-
world implementation. Clin. Pharmacol. Ther. 94, 207–210. doi: 10.1038/clpt.
2013.59
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2016 Frick, Benton, Scolaro, McLaughlin, Bradley, Suzuki, Wang and
Wiltshire. This is an open-access article distributed under the terms of the Creative
Commons Attribution License (CC BY). The use, distribution or reproduction in
other forums is permitted, provided the original author(s) or licensor are credited
and that the original publication in this journal is cited, in accordance with accepted
academic practice. No use, distribution or reproduction is permitted which does not
comply with these terms.
Frontiers in Pharmacology | www.frontiersin.org 11 August 2016 | Volume 7 | Article 241
